



Clients only need to provide compounds targeting the desired biological target (2–3 mg per compound). We will arrange the corresponding screening and testing services and deliver a professional analytical report.
For any inquiries, please contact our team for prompt assistance.
Enzymology research has always been an important part of drug development AnyMol has extensive experience in enzymatic screening, such as kinase profile screening, and enzymatic experiments cover more than 300 screening models Including common histone deacetylases, histone demethylases, tyrosine kinases, serine kinases, methyltransferases Phosphodiesterases, DNA repair enzymes, heat shock proteins, immune-related proteins, etc.
Flexible project implementation plans can be provided according to the number of compounds, and 96-well and 384-well plate screening modes can be provided to accelerate your drug development process
| Enzyme | Target | |
|---|---|---|
| Kinase | ABL1s,ACK,AKTs,AMPKs,Auroras,etc. | ADP-Glo |
| Bromodomains | ATADs,BAZ2B,BPTF/FALZ,etc. | TR-FRET/AlphaScreen |
| Deacetylases | HDAC1/2/3/4/5/6/7/8/9,SIRT1/2/3/5,etc. | Fluorogenic |
| Demethylases | FBXL10/11,JARID1A/B/C/D,JMJD1A,etc. | AlphaScreen/Chemiluminescent |
| Heat shock protein | HSP90α,HSP90β,etc. | AlphaScreen |
| Immnotherapy related | ARG,CD,CTLA4,GITRL,IDO,etc. | Colorimetric/Fluorogenic |
| Methyl-lysine | CBX1,L3MBTL1,etc. | AlphaScreen/Fluorogenic |
| Methyltransferases | DNMTs,DOT1L,EHMT1/GLP,EZHs,etc | Chemiluminescence |
| PARPs | PARP1/2/3/6/7/10/11/14/15,TNKS1/S2,etc. | Chemiluminescence/Colorimetric |
| Phosphodiesterase | PDEs,Autotaxin,etc. | TR-FRET/FP/Fluorogenic |
| Protease | DPP3/4/7/8/9,FAP,POP,Renin,etc. | Fluorogenic |
| Others | COX,Myeloperoxidase,FAAH,FABP4,etc. | FP/colorimetric/Fluorogenic |
Biochemical detection analysis: ADP-Glo detection, Fluorescence detection method, Absorbance detection, TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) detection of substrate phosphorylation levels, Chemiluminescence detection, etc.




